These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 20975064

  • 1. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
    Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR, American Society of Clinical Oncology, American Society of Hematology.
    J Clin Oncol; 2010 Nov 20; 28(33):4996-5010. PubMed ID: 20975064
    [Abstract] [Full Text] [Related]

  • 2. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
    Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR, American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee.
    Blood; 2010 Nov 18; 116(20):4045-59. PubMed ID: 20974674
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 Nov 18; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun 18; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 7. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 18; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 8. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.
    Lung Cancer; 2012 Jun 18; 76(3):478-85. PubMed ID: 22277104
    [Abstract] [Full Text] [Related]

  • 9. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A, Edelsberg J, Kallich J, Oster G.
    Clin Ther; 2008 Jan 18; 30(1):206-18. PubMed ID: 18343258
    [Abstract] [Full Text] [Related]

  • 10. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM, Black CD.
    Ann Pharmacother; 2008 Dec 18; 42(12):1865-70. PubMed ID: 19017828
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
    Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA.
    J Clin Oncol; 2009 Jun 10; 27(17):2838-47. PubMed ID: 19380447
    [Abstract] [Full Text] [Related]

  • 13. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
    Hess G, Hill J, Clough J, Hulnick S, Nordyke RJ.
    Curr Med Res Opin; 2008 Mar 10; 24(3):815-9. PubMed ID: 18257979
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB, Coyne DW.
    Mayo Clin Proc; 2007 Nov 10; 82(11):1371-80. PubMed ID: 17976358
    [Abstract] [Full Text] [Related]

  • 16. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.
    Clin Ther; 2006 Jun 10; 28(6):801-31. PubMed ID: 16860166
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
    Crouch Z, DeSantis ER.
    Am J Health Syst Pharm; 2009 Jul 01; 66(13):1180-5. PubMed ID: 19535656
    [Abstract] [Full Text] [Related]

  • 19. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 01; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 20. Anemia management in oncology and hematology.
    Spivak JL, Gascón P, Ludwig H.
    Oncologist; 2009 Jan 01; 14 Suppl 1():43-56. PubMed ID: 19762516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.